Dogwood (DWTX) Therapeutics announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP, evaluating Halneuron for the treatment of neuropathic pain associated with prior chemotherapy treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX: